Product
Dotarem
Aliases
gadoterate meglumine
Name
Gadoterate Meglumine
INN Name
gadoterate meglumine
FDA Approved
Yes
4 clinical trials
4 organizations
13 indications
3 documents
Indication
GadoliniumIndication
MultiHanceIndication
DotaremIndication
Magnetic Resonance ImagingIndication
Gadolinium RetentionIndication
Brain TumorIndication
PrimaryIndication
RecurrentIndication
Breast NeoplasmsIndication
Breast DiseasesIndication
FibroadenomaIndication
Interstitial Lung DiseaseIndication
Breast CancerClinical trial
Gadolinium Retention in Human Bone Tissue in Pediatric Patients: A Comparison of Dotarem Versus MultiHance MRI Contrast AgentsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Performance of Elucirem® (Gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) Perfusion of Brain Gliomas Phase IIIb Clinical TrialStatus: Recruiting, Estimated PCD: 2024-04-29
Clinical trial
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)Status: Completed, Estimated PCD: 2023-06-30
Clinical trial
Collagen-targeted PET Imaging for Early Interstitial Lung DiseaseStatus: Recruiting, Estimated PCD: 2024-04-01
Document
DailyMed Label: DOTAREMOrganization
Guerbet LLCOrganization
Slate Run Pharmaceuticals, LLCOrganization
Fresenius Kabi USA, LLC
Document
DailyMed Label: CLARISCANOrganization
GE Healthcare Inc.